• LAST PRICE
    48.4600
  • TODAY'S CHANGE (%)
    Trending Up1.4300 (3.0406%)
  • Bid / Lots
    48.3400/ 6
  • Ask / Lots
    48.5000/ 6
  • Open / Previous Close
    47.2800 / 47.0300
  • Day Range
    Low 47.1000
    High 48.9400
  • 52 Week Range
    Low 12.2800
    High 51.6100
  • Volume
    402,975
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 47.03
TimeVolumeVERA
09:32 ET150347.1
09:33 ET40047.27
09:35 ET20047.345
09:37 ET10047.33
09:39 ET40047.15
09:42 ET240047.5699
09:44 ET70047.535
09:46 ET30047.47
09:48 ET61147.445
09:50 ET111547.87
09:51 ET229747.67
09:53 ET90047.68
09:55 ET10047.595
09:57 ET20047.685
10:00 ET10047.68
10:02 ET90047.66
10:06 ET60647.585
10:08 ET366248.24
10:09 ET210048.315
10:11 ET82248.32
10:13 ET50048.43
10:15 ET619348.39
10:18 ET299248.3
10:20 ET485448.43
10:22 ET128548.325
10:24 ET30048.36
10:26 ET50048.51
10:27 ET154948.325
10:31 ET94048.245
10:33 ET50048.225
10:36 ET90948.38
10:38 ET10048.42
10:40 ET70048.7403
10:44 ET169948.69
10:45 ET236648.62
10:47 ET131448.48
10:49 ET80048.48
10:51 ET73548.51
10:54 ET10048.535
10:56 ET1403448.5
10:58 ET83248.39
11:00 ET133348.38
11:02 ET82648.32
11:03 ET47648.45
11:05 ET1783148.5
11:07 ET477848.39
11:09 ET50048.34
11:12 ET13548.375
11:14 ET150048.48
11:16 ET20048.515
11:18 ET40048.45
11:20 ET5200048.81
11:23 ET40048.9
11:25 ET60048.75
11:27 ET87148.71
11:30 ET29548.66
11:32 ET10048.765
11:34 ET236148.85
11:36 ET43648.8
11:38 ET682548.72
11:39 ET180048.61
11:41 ET30048.62
11:43 ET170048.665
11:45 ET10048.715
11:48 ET603648.7
11:50 ET100048.665
11:52 ET10048.665
11:54 ET50048.68
11:56 ET50048.7
11:57 ET20048.74
11:59 ET20048.74
12:01 ET30048.61
12:03 ET20048.69
12:06 ET795048.69
12:08 ET148048.73
12:10 ET20048.78
12:12 ET112548.6743
12:14 ET20048.6
12:15 ET10048.63
12:17 ET30048.57
12:19 ET65948.64
12:24 ET98948.78
12:26 ET160048.78
12:28 ET471648.67
12:30 ET426048.65
12:32 ET1272548.54
12:33 ET1621848.7
12:35 ET395148.7
12:37 ET6234448.585
12:39 ET141248.76
12:42 ET150448.6005
12:44 ET10048.735
12:46 ET357648.56
12:48 ET232048.69
12:50 ET10048.66
12:51 ET260148.46
12:53 ET80348.53
12:55 ET50048.49
12:57 ET20048.52
01:00 ET140048.5
01:02 ET657648.42
01:04 ET110048.41
01:06 ET10048.5
01:08 ET130048.33
01:11 ET30048.41
01:13 ET129548.43
01:15 ET50048.52
01:18 ET265048.4
01:20 ET30048.39
01:22 ET10048.35
01:24 ET265048.395
01:26 ET494748.375
01:27 ET44348.36
01:29 ET20048.405
01:31 ET40048.45
01:33 ET52048.35
01:36 ET50048.43
01:38 ET810148.7
01:40 ET120048.505
01:42 ET30048.505
01:44 ET40048.42
01:45 ET10048.5
01:47 ET112948.435
01:49 ET40048.36
01:51 ET100048.46
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVERA
Vera Therapeutics Inc
3.0B
-18.6x
---
United StatesXENE
Xenon Pharmaceuticals Inc
3.0B
-14.6x
---
United StatesDYN
Dyne Therapeutics Inc
3.0B
-8.4x
---
United StatesEWTX
Edgewise Therapeutics Inc
3.0B
-21.7x
---
United StatesVRNA
Verona Pharma PLC
3.1B
-20.5x
---
United StatesVSBC
Vitaspring Biomedical Co. Ltd
3.1B
3,311.3x
---
As of 2024-11-22

Company Information

Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants. The Company is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which it refers to as ORIGIN 3, and completing the open label extension of its Phase 2b clinical trial in IgAN, which it refers to as ORIGIN 2b.

Contact Information

Headquarters
2000 Sierra Point Parkway, Suite 1200BRISBANE, CA, United States 94005
Phone
650-770-0077
Fax
302-655-5049

Executives

Independent Non-Executive Chairman of the Board
Michael Morrissey
President, Chief Executive Officer, Founder, Director
Marshall Fordyce
Chief Financial Officer
Sean Grant
Chief Operating Officer
David Johnson
Chief Medical Officer
Robert Brenner

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.0B
Revenue (TTM)
$0.00
Shares Outstanding
63.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.05
EPS
$-2.60
Book Value
$2.29
P/E Ratio
-18.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.